Adverse events related to topical drug treatments for acne vulgaris

References

• Collier CN, Harper JC, Cantrell WC, et al. The prevalence of acne in adults 20 years and older. JAAD. 2008;58:56–59.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL. Acne Vulgaris. N Engl J Med. 2018;379:1343–1352.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lynde C, Kunynetz R, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. JCMS. 2003;7:31–37.
   Google Scholar
• Degitz K, Placzek M, Borelli C, et al. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5:316–323.
   PubMedGoogle Scholar
• Ferri FF. Ferri’s clinical advisor: acne vulgaris. London: Elsevier; 2019.
   Google Scholar
• Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. JEADV. 2016;30(8):1261–1268.
   Google Scholar
• Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Women Dermatol. 2018;4:56–71.
   PubMedGoogle Scholar
• Kainz JT, Berghammer G, Auer-Grumbach P, et al. Azelaic acid 20 % cream: effects on quality of life and disease severity in adult female acne patients. J Dtsch Dermatol Ges. 2016;14:1249–1259.
   Web of Science ®Google Scholar
• Szepietowski J, Kapinska-Mrowiecka M, Kaszuba A, et al. Tradzik zwyczajny: patogeneza i leczenie. Konsensus Polskiego Towarzystwa Dermatologicznego. Przeglad Dermatol. 2012;99:649–673.
   Google Scholar
• Gollnick HP, Bettoli V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne patients. JEADV. 2016;30:1480–1490.
   Google Scholar
• Gollnick H. Current concepts of the pathogenesis of acne implications for drug treatment. Drugs. 2003;63:1579–1596.
   PubMed Web of Science ®Google Scholar
• Akhavan A, Bershad S. Topical acne drugs review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:474–492.
   Web of Science ®Google Scholar
• Taylor GA, Shalita AR. Benzoyl peroxide-based combination therapies for acne vulgaris a comparative review. Am J Clin Dermatol. 2004;5:261–265.
   PubMed Web of Science ®Google Scholar
• Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG. 2006;4:293–300.
   Google Scholar
• Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10:2555–2562.
   PubMed Web of Science ®Google Scholar
• Mills OH, Klicman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;10:664–667.
   Google Scholar
• Cunliffe WJ, Burke B. Benzoyl peroxide: lack of sensitization. Acta Derm Venereol. 1982;62:458–459.
   PubMed Web of Science ®Google Scholar
• Veraldi S, Brena M, Barbareschi M. Allergic contact dermatitis caused by topical antiacne drugs. Expert Rev Clin Pharmacol. 2015;8(4):377–381.
   PubMed Web of Science ®Google Scholar
• Lindemayr H, Drobil M. Contact sensitization to benzoyl peroxide. Contact Dermat. 1981;7:137–140.
   PubMed Web of Science ®Google Scholar
• Nacht S, Yeung D, Beasley JN Jr, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. JAAD. 1981;4:31–37.
   PubMed Web of Science ®Google Scholar
• Tan JKL. Adapalene 0.1% and benzoyl peroxide 2.5%: a novel combination for treatment of acne vulgaris. Skin Therapy Lett. 2009;14:4–5.
   PubMedGoogle Scholar
• Krautheim A, Gollnick HPM. Acne: topical treatment. Clin Dermatol. 2004;22:398–407.
   PubMed Web of Science ®Google Scholar
• Bladon PT, Burke BM, Cunliffe WJ, et al. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br J Dermatol. 1986;114:493–499.
   PubMed Web of Science ®Google Scholar
• Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379:361–372.
   PubMed Web of Science ®Google Scholar
• Tripathi SV, Gustafson CJ, Huang KE, et al. Side effects of common acne treatments. Expert Opin Drug Saf. 2013;12:39–51.
   PubMed Web of Science ®Google Scholar
• Hauk L. Acne vulgaris: treatment guidelines from the AAD. Am Fam Physician. 2017;95:740–741.
   PubMed Web of Science ®Google Scholar
• Balkrushnan R, Bhosle MJ, Camacho F, et al. Prescribing patterns for topical retinoids: analyses of 15 years of data from the national ambulatory medical care survey. J Dermatological Treat. 2010;21:193–200.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in acne – an evidence-based overview. J Dtsch Dermatol Ges. 2008;6:1023–1031.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Pecone D, Pona A, et al. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20:345–365.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Gollnick H. Topical retinoids in acne vulgaris update on efficacy and safety. Am J Clin Dermatol. 2008;9:369–381.
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. JAAD. 1997;36:126–134.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Jarratt M, Schlessinger J, et al. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2010;9:639–646.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Lux A, Wiede A, et al. A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. JEADV. 2015;29:789–796.
   Google Scholar
• Rao GR, Ghosh S, Dhurat R, et al. Efficacy, safety and tolerability of microsphere adapalene vs. conventional adapalene for acne vulgaris. Int J Dermatol. 2009;48:1360–1365.
   PubMed Web of Science ®Google Scholar
• Weiss JS, Thiboutot DM, Hwa J, et al. Long-term safety and efficacy study of adapalene 0.3% gel. J Drugs Dermatol. 2008;7:24–28.
   PubMed Web of Science ®Google Scholar
• Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. JAAD. 1996;34:482–485.
   PubMed Web of Science ®Google Scholar
• Alan Clucas A, Verschoore M, Sorba V, et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. JAAD. 1997;36:116–118.
   Web of Science ®Google Scholar
• Caron D, Sorba V, Kerrouche N, et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. JAAD. 1997;36:110–112.
   PubMed Web of Science ®Google Scholar
• Tu P, Li GQ, Zhu XJ, et al. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. JEADV. 2001;15:31–36.
   Google Scholar
• Johnson BA, Nunley JR. Topical therapy for acne vulgaris. Postgrad Med. 2015;107:69–80.
   Google Scholar
• Gregoriou S, Kritsotaki E, Katoulis A, et al. Use of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Invest Dermatol. 2014;7:165–170.
   PubMedGoogle Scholar
• Pariser D, Colon LE, Johnson LA, et al. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7:18–23.
   PubMed Web of Science ®Google Scholar
• Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis. 2005;75:14–22.
   PubMed Web of Science ®Google Scholar
• Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45–50.
   PubMed Web of Science ®Google Scholar
• Marks R. Pharmacokinetics and safety review of tazarotene. JAAD. 1998;39:134–138.
   PubMed Web of Science ®Google Scholar
• Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350:339.
   PubMed Web of Science ®Google Scholar
• Panchaud A, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52:1844–1851.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131:163–186.
   PubMed Web of Science ®Google Scholar
• Pochi PE, Bagatell FK, Ellis CN, et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis. 1988;41:132–136.
   PubMed Web of Science ®Google Scholar
• Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol. 1981;117:551–553.
   PubMedGoogle Scholar
• Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148:467–478.
   PubMed Web of Science ®Google Scholar
• Honzak L, Šentjurc M. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflugers Arch. 2000;440:44–45.
   PubMed Web of Science ®Google Scholar
• Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris. Arch Dermatol. 1981;117:482–485.
   PubMed Web of Science ®Google Scholar
• Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol. 1986;122:583–584.
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Li LF, Tu YT, et al. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatological Treat. 2004;15:372–378.
   PubMedGoogle Scholar
• Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. JAAD. 1990;22:489–495.
   PubMed Web of Science ®Google Scholar
• Zeichner JA. Optimizing topical combination therapy for the treatment of acne vulgaris. J Drugs Dermatol. 2012;11:313–317.
   PubMed Web of Science ®Google Scholar
• Gollnick HPM, Draelos Z, Glenn MJ, et al. Adapalene–benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. BJD. 2009;161:1180–1189.
   Google Scholar
• Gold LS, Werschler WP, Mohawk J. Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. JDD. 2017;16:582–588.
   Google Scholar
• Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18:524–526.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5:37–42.
   PubMed Web of Science ®Google Scholar
• Tschen EH, Katz HI, Jones TM, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis. 2001;67:165–169.
   PubMed Web of Science ®Google Scholar
• Chalker DK, Shalita A, Smith JG Jr, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. JAAD. 1983;9:933–936.
   PubMed Web of Science ®Google Scholar
• Habbema L, Koopmans B, Menke HE. A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. Br J Dermatol. 1989;121:497–502.
   PubMed Web of Science ®Google Scholar
• Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. JEADV. 2007;21:311–319.
   Google Scholar